<p>This is a summary of the European public assessment report (EPAR) for Talmanco. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Talmanco.</p><p>For practical information about using Talmanco, patients should read the package leaflet or contact their doctor or pharmacist.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Talmanco is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.</p></div>
Therapeutic Area (MeSH)
ATC Code
G04BE08
ATC Item
N/A
Pharmacotherapeutic Group
Urologicals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| tadalafil | N/A | tadalafil |
EMA Name
Talmanco (previously Tadalafil Generics)
Medicine Name
Talmanco (previously Tadalafil Generics)
Aliases
N/ANo risk management plan link.
